Breast Recurrence Score Test Articles & Analysis
10 news found
(NASDAQ: EXAS), a global leader in cancer diagnostics, today announced the presentation of new data at the 2021 San Antonio Breast Cancer Symposium (SABCS) supporting the clinical value of the Oncotype DX Breast Recurrence Score test. ...
Based on the RxPONDER results, the National Comprehensive Cancer Network (NCCN) v updated its guidelines for breast cancer and recognised the Oncotype DX Breast Recurrence Score test as the only test that can be used for prediction of chemotherapy benefit in early-stage breast ...
The National Comprehensive Cancer Network (NCCN)viii recently updated its guidelines for breast cancer and recognised the Oncotype DX Breast Recurrence Score test as the only test that can be used for prediction of chemotherapy benefit in early-stage breast cancer patients with ...
Exact Sciences today announced that its Oncotype DX Breast Recurrence Score test has been recognised as the only test that can be used for prediction of chemotherapy benefit in early-stage breast cancer patients with 1-3 positive axillary lymph nodes, including micro metastases, by the National ...
SEATTLE, Dec. 09, 2020 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived tumor organoids, today presented data from a study summarizing the predictive value of the PARIS® Test in breast cancer tumors as a poster session (PS04/01) at the 2020 San Antonio Breast Cancer Symposium, taking place ...
Study results presented at ASCO20 showed that the Recurrence Score results on core biopsies predict the likelihood of response to neoadjuvant chemotherapy Results are particularly relevant in the context of the Covid-19 pandemic which is causing the delay of elective surgeries across health systems worldwide Exact Sciences Corp. today announced results from ...
Data obtained in real-life setting from more than 800 patients with node-negative or nodepositive early-stage breast cancer highlight the test’s impact on clinical practice with chemotherapy-sparing effect Publication of landmark TAILORx study results led to greater reduction in chemotherapy recommendations Exact Sciences Corp. today announced results ...
(NASDAQ: EXAS) today announced new outcomes data from two large population-based studies1,2 presented at the 2019 San Antonio Breast Cancer Symposium (SABCS). The real-world evidence suggests that use of the Oncotype DX Breast Recurrence Score test in clinical practice is consistent with previous clinical ...
“Last year, TAILORx established the highest level of evidence and unprecedented precision supporting the use of the Oncotype DX Breast Recurrence Score test to guide adjuvant chemotherapy treatment for women with early- stage breast cancer,” said lead author Joseph A. ...
Conventional biological wisdom holds that living cells interact with their environment through an elaborate network of chemical signals. As a result many therapies for the treatment of cancer and other diseases in which cell behavior goes awry focus on drugs that block or disrupt harmful chemical signals. Now, a new road for future therapies may have been opened with scientific evidence for a ...